Meeting
2023 ASCO Genitourinary Cancers Symposium
Early switching to pembrolizumab (Pe) during first-line platinum-based chemotherapy (PCT) in patients (pts) with metastatic urothelial carcinoma (mUC).
Authors
Yuki Endo
Department of Urology, Nippon Medical School Hospital, Tokyo, Japan
Yuki Endo , Go Kimura , Jun Akatsuka , Hayato Takeda , Masato Yanagi , Hikaru Mikami , Hiroya Hasegawa , Mami Taniuchi , Akifumi Katsu , Ryota Funato , Yuka Toyama , Yukihiro Kondo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Cancer Disparities
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 452)
DOI
10.1200/JCO.2023.41.6_suppl.452
Abstract #
452
Poster Bd #
G12
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Trends over time in the proportion of sequential treatment and overall survival in patients with metastatic urothelial carcinoma in real-world practice.
First Author: Shoma Yamamoto
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Prognostic effects of co-occurring TP53 and KRAS aberrations in patients with advanced biliary tract cancer.
First Author: Taro Shibuki
Poster
2023 ASCO Annual Meeting
TROPHY-U-01 Cohort 4 (C4): Sacituzumab govitecan (SG) in combination with cisplatin (cis) as first-line (1L) therapy, followed by maintenance avelumab plus (+) SG or zimberelimab (zim) + SG in patients (pts) with treatment (Tx)-naïve metastatic urothelial cancer (mUC).
First Author: Chethan Ramamurthy
Poster
2023 ASCO Genitourinary Cancers Symposium
US real-world first-line (1L) treatment patterns and outcomes for patients with metastatic urothelial carcinoma (mUC) following maintenance avelumab approval.
First Author: Haojie Li